HUT75375A - Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells - Google Patents

Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells

Info

Publication number
HUT75375A
HUT75375A HU9602182A HU9602182A HUT75375A HU T75375 A HUT75375 A HU T75375A HU 9602182 A HU9602182 A HU 9602182A HU 9602182 A HU9602182 A HU 9602182A HU T75375 A HUT75375 A HU T75375A
Authority
HU
Hungary
Prior art keywords
hiv
cells
receptor
chimeric
infected cell
Prior art date
Application number
HU9602182A
Other languages
English (en)
Other versions
HU220100B (hu
HU9602182D0 (en
Inventor
Babak Banapour
Waldemar Kolanus
Charles Romeo
Brian Seed
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of HU9602182D0 publication Critical patent/HU9602182D0/hu
Publication of HUT75375A publication Critical patent/HUT75375A/hu
Publication of HU220100B publication Critical patent/HU220100B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
HU9602182A 1994-02-14 1995-01-12 HIV-fertőzött sejtekkel szembeni sejtszintű immunválasz kiváltására képes kimérareceptort expresszáló terápiás sejtek és alkalmazásuk HU220100B (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19539594A 1994-02-14 1994-02-14
US08/284,391 US5851828A (en) 1991-03-07 1994-08-02 Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
PCT/US1995/000454 WO1995021528A1 (en) 1994-02-14 1995-01-12 Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells

Publications (3)

Publication Number Publication Date
HU9602182D0 HU9602182D0 (en) 1996-10-28
HUT75375A true HUT75375A (en) 1997-05-28
HU220100B HU220100B (hu) 2001-10-28

Family

ID=26890956

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9602182A HU220100B (hu) 1994-02-14 1995-01-12 HIV-fertőzött sejtekkel szembeni sejtszintű immunválasz kiváltására képes kimérareceptort expresszáló terápiás sejtek és alkalmazásuk

Country Status (21)

Country Link
US (3) US5851828A (hu)
EP (1) EP0750457B1 (hu)
JP (1) JP3832850B2 (hu)
KR (1) KR100289253B1 (hu)
CN (1) CN1318576C (hu)
AT (1) ATE308888T1 (hu)
AU (1) AU690204B2 (hu)
BR (1) BR9506783A (hu)
CA (1) CA2182890C (hu)
CZ (1) CZ293969B6 (hu)
DE (1) DE69534589T2 (hu)
DK (1) DK0750457T3 (hu)
ES (1) ES2249766T3 (hu)
FI (1) FI120264B (hu)
HU (1) HU220100B (hu)
IL (1) IL112390A (hu)
NO (1) NO319378B1 (hu)
NZ (1) NZ279123A (hu)
PL (1) PL180066B1 (hu)
UA (1) UA42760C2 (hu)
WO (1) WO1995021528A1 (hu)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407221B1 (en) 1990-12-14 2002-06-18 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
ATE236973T1 (de) * 1993-07-16 2003-04-15 Gen Hospital Corp Änderung der zellulären immunität durch rezeptorchimäre
PT781095E (pt) * 1994-08-02 2003-06-30 Gen Hospital Corp Celulas contendo receptores chamariz cd4 e moleculas e metodos com elas relacionados
GB9520641D0 (en) * 1995-10-10 1995-12-13 Medical Res Council Improvements in or relating to protection against intracellular infection
AUPN980796A0 (en) 1996-05-13 1996-06-06 Australian Membrane And Biotechnology Research Institute Improved reservoir components
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6610043B1 (en) 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
GB9925853D0 (en) * 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
DE19957838C2 (de) * 1999-11-25 2002-11-21 Pette Heinrich Inst Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
EP2031646A4 (en) * 2006-06-22 2012-05-30 River Bell Co TREATMENT DEVICE, TREATMENT METHOD AND PLASMA SOURCE
WO2009139930A2 (en) 2008-05-16 2009-11-19 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
ES2620259T3 (es) 2010-04-14 2017-06-28 Roger Williams Medical Center Métodos y composiciones para tratar VIH
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
CA3133302A1 (en) 2012-07-20 2014-01-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
US10780118B2 (en) * 2012-08-20 2020-09-22 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3261651B1 (en) * 2015-02-27 2022-05-04 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
AU2016264623B2 (en) 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US10738099B2 (en) 2015-09-22 2020-08-11 The Trustees Of The University Of Pennsylvania Method of redirecting T cells to treat HIV infection
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
CN106267409B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病生物治疗反应器
CN106178163B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病生物细胞免疫治疗仪
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CA3045017A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
US11965892B2 (en) 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018189360A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
WO2018195019A1 (en) 2017-04-18 2018-10-25 The Broad Institute Inc. Compositions for detecting secretion and methods of use
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN107014658B (zh) * 2017-05-27 2023-08-25 四川省肿瘤医院 提取游离细胞的方法及试剂盒
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
JP6731114B2 (ja) 2017-08-03 2020-07-29 タイガ バイオテクノロジーズ，インク． メラノーマの処置のための方法および組成物
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CA3073848A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
US11732257B2 (en) 2017-10-23 2023-08-22 Massachusetts Institute Of Technology Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US20200368280A1 (en) * 2018-01-12 2020-11-26 Viracta Therapeutics, Inc. Epigenetic modifiers for use in cellular immunotherapy
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2019241273A1 (en) 2018-06-11 2019-12-19 The Broad Institute, Inc. Lineage tracing using mitochondrial genome mutations and single cell genomics
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US20210177832A1 (en) 2018-08-20 2021-06-17 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
US20210355522A1 (en) 2018-08-20 2021-11-18 The Broad Institute, Inc. Inhibitors of rna-guided nuclease activity and uses thereof
WO2020041387A1 (en) 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
WO2020092057A1 (en) 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
BR112021012278A2 (pt) 2018-12-21 2021-12-14 Biontech Us Inc Método e sistema para a preparação de células hla de classe ii-específica de epitopes e de síntese de cd4 + t
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020191079A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
WO2022036180A1 (en) 2020-08-13 2022-02-17 Yale University Compositions and methods for engineering and selection of car t cells with desired phenotypes
WO2023173137A1 (en) 2022-03-11 2023-09-14 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
WO2023220644A1 (en) 2022-05-10 2023-11-16 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
CN115747166A (zh) * 2022-10-13 2023-03-07 上海怡豪生物科技有限公司 一种通用型car-t细胞及其制备方法与应用
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024155821A1 (en) 2023-01-18 2024-07-25 Yale University Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL224379A (hu) 1957-01-30
US4873190A (en) * 1984-06-13 1989-10-10 Massachusetts Institute Of Technology Heterodimeric T lymphocyte receptor
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988001649A1 (en) * 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6463394A (en) * 1987-09-04 1989-03-09 Kyowa Hakko Kogyo Kk Novel chimera polypeptide
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
ZA89430B (en) * 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
CA2000878C (en) * 1988-10-18 1999-06-29 Jean-Pierre Kinet Cdnas coding for the subunit of the high-affinity receptor for immunoglobulin e
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
FR2644463A1 (hu) * 1989-03-17 1990-09-21 Pasteur Institut
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
WO1991010736A2 (en) * 1990-01-19 1991-07-25 Dana Farber Cancer Institute CLONING AND CHARACTERIZATION OF THE CD3θ SUBUNIT
CA2074825C (en) * 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6753162B1 (en) * 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
IE920716A1 (en) * 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) * 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
ATE236973T1 (de) 1993-07-16 2003-04-15 Gen Hospital Corp Änderung der zellulären immunität durch rezeptorchimäre
US5439819A (en) * 1993-08-27 1995-08-08 The Regents Of The University Of California Chimeric protein tyrosine kinases
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
JP3782521B2 (ja) 1996-08-23 2006-06-07 富士通コンポーネント株式会社 押釦構造およびキーボード

Also Published As

Publication number Publication date
PL315908A1 (en) 1996-12-09
US7094599B2 (en) 2006-08-22
NO319378B1 (no) 2005-07-25
NZ279123A (en) 1998-03-25
ES2249766T3 (es) 2006-04-01
JPH09512421A (ja) 1997-12-16
IL112390A (en) 2006-08-20
FI963150A0 (fi) 1996-08-12
CN1146136A (zh) 1997-03-26
UA42760C2 (uk) 2001-11-15
CZ293969B6 (cs) 2004-09-15
US20030138410A1 (en) 2003-07-24
KR970701004A (ko) 1997-03-17
WO1995021528A1 (en) 1995-08-17
CA2182890A1 (en) 1995-08-17
US6284240B1 (en) 2001-09-04
CN1318576C (zh) 2007-05-30
DE69534589D1 (de) 2005-12-15
CA2182890C (en) 2008-11-04
FI120264B (fi) 2009-08-31
IL112390A0 (en) 1995-03-30
US5851828A (en) 1998-12-22
DE69534589T2 (de) 2006-07-13
AU690204B2 (en) 1998-04-23
KR100289253B1 (ko) 2001-11-30
DK0750457T3 (da) 2006-03-27
HU220100B (hu) 2001-10-28
BR9506783A (pt) 1997-10-14
AU1565395A (en) 1995-08-29
HU9602182D0 (en) 1996-10-28
NO963379L (no) 1996-10-11
PL180066B1 (pl) 2000-12-29
CZ233196A3 (en) 1997-07-16
MX9603384A (es) 1997-12-31
JP3832850B2 (ja) 2006-10-11
EP0750457B1 (en) 2005-11-09
ATE308888T1 (de) 2005-11-15
EP0750457A1 (en) 1997-01-02
FI963150A (fi) 1996-10-10
NO963379D0 (no) 1996-08-13
EP0750457A4 (en) 1999-03-03

Similar Documents

Publication Publication Date Title
HU9602182D0 (en) Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells
ZA961477B (en) Redirection of cellular immunity by receptor chimeras.
WO2002077029A3 (en) Cd19-specific redirected immune cells
ZA961476B (en) Redirection of cellular immunity by protein-tyrosine kinase chimeras
IL114778A0 (en) Chimeric CD4 receptor-bearing cells membrane-bound receptors and DNA encoding the same
AU712245C (en) Redirection of cellular immunity by receptor chimeras
NZ330034A (en) Method of treating HIV in mammals by administering cells bearing CD4 decoy receptors